GB2226759A - Pharmaceutical compositions containing lysine - Google Patents
Pharmaceutical compositions containing lysine Download PDFInfo
- Publication number
- GB2226759A GB2226759A GB8900048A GB8900048A GB2226759A GB 2226759 A GB2226759 A GB 2226759A GB 8900048 A GB8900048 A GB 8900048A GB 8900048 A GB8900048 A GB 8900048A GB 2226759 A GB2226759 A GB 2226759A
- Authority
- GB
- United Kingdom
- Prior art keywords
- aminoethanol
- hydroxylysine
- lysine
- drugs according
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims description 7
- 239000004472 Lysine Substances 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 9
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 9
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 9
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 3
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical class [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
1 0, k. f 1 .. - k - 4 0 1 Drugs Containing Isomers-of Hydroxylysine or
Lysine.
:z-k:2 (s,e:5 E' c 1 1 1 11 I- t -X D - A The invpntion relates to drugs containing, by way of effective agents, at least one isomer of hydroxylysine or lysine, or of their pharmaceutically acceptable derivatives, together with usual carriers and/or adjuvants, as the case may be. Note is to be take -of the fact that said isomer of hydroxylysine or lysine may be present in its L or D configuration, said L configuration being preferred; that the hydroxyl group may be located in various positions from beta to delta along the carbon chain, 'S&id delta position being the preferred one; and that as regards the ster.eo- isomeric position of said hydroxyl group in respect of an asymmetrically placed carbon atom, both isomers are pharmaceutically useful.
The effectiveness of said drugs may be enhanced by adding N-methylaminoethanol and/or N-dimethyl-aminoethanol, for instance as acid addition salts.
J.
(0 -'d 0 3 The structural formulae of the above compounds, already fl known, are shown only for the sake of completeness.
C1, 4 2 -/1 0 Al P Mr 5 t. H,: 1 L., H l2 N - 00 A_ 3 i,,l k t, - tJ -- t i, 1 ' 1! - 1 '1 4 _I The compounds as such are known and can be produced by methods already known.
The drugs according: to the invention may contain hydroxylysine or lysine isomers in the form of pharmaceutically compatible derivatives, and more particularly those converted, within the body, into the free form of said derivatives. This class of compounds includes more particularly alkali salts, alkaline earth salts, acid addition salts, esters, amides and ethers of hydroxylysine or lysine and their N-alkyl derivatives as well as the oligopeptides or polypeptides thereof.
I; I -- J..
(.0 The drugs according to the invention serve to treat the followi.Ag disorders, whether administered alone or in support of any conventional therapy. Currently, conventional therapies arb frequently insatisfactory, a fact demonstrated if only by the not insignificant number of cases where surgical intervention can still not be avoided.
0 Fields of application for the drugs according to the invention:
1. Affections of the venous system: above all dilatations and phlebitic changes in veins as well as variqoceles and hemorrhoids, affections of dura mater sinuses or similar syndromes.
2. Cardiac affections: above all endocarditis and its sequels but also myocarditis and its sequels, arrhythmias being most prominent among the latter ones.
3. Scarlatina, rheumatic fever, septic athropathies, erysipelas, impetigo, etc.
4. Prostatites and adnexites 5. Anal fissures 6. Dental caries 7. Neurological diseases and more particularly those entailing motor and/or sensitivity disturbances.
8. Hernias ---4 0 6 In all,cases mentioned above, the effective principle resides in a strengthening, caused by the drugs according to the invention., of intra and extra-cellular fibre systems.
The drugs according to the invention are to be administered in ways basically similar to those normally employed in usual amino acid treatment, i.e. preferentially per os or intravenously, or by the central intravenous route. Administration by way of tablets, coated tablets, injection or infusion soluti'ons-. would likewise be identical.
With superficially accessible foci, localized administration in the form of solutions or powders or salves or similar compounds might be considered.
17 In view of the fact that the compounds in question are non-toxic, dosages may range widely even though they might initially be based on normally used therapeutical amino acid dosage levels of between 0.01 and 0.1 g of substance per kg of bodyweight.
Contraindications applicable to all amino acids will have to be taken into account.
Pharmaceutical production and processing will be performed in the usual Mnner, all legal rules and regulations concerning purity of substance;sterilization, absence of pyrogens, etc. being observed.
1 1 claims:., 1. Drugs containing, as active ingredients, at least one isomer of hydroxylysine or lysine, or one of their pharmaceutically acceptable derivatives, if nec-essary together with usual carriers and/or adjuvants.
Claims (1)
- 2. Drugs according to Claim 1, characterized in that hydroxylysine orlysine will be present as L-form compounds.3. Drugs according to one of Claims 1 - 2, characterized in that the hydroxyl group of hydroxylysine is loca - ted in the delta position.4. Drugs according to one of Claims 1 - 3, characterized in that the hydroxyl group of hydroxylysine is in one of the two isomeric alpha or beta positions.Enhancement of the effectiveness of a drug according to Claims 1 - 4 by the addition of N-methyl-aminoethanol and/or N-dimethyl-aminoethanol.6. Enhancement of the effectiveness of a drug according to Claims 1 - 5, characterized in that said added substances, N-methyl-aminoethanol and/or N-dimethyl-aminoethanol, are present in the form of acid addition saits.Published 1990 at The Patent Office. State House, 66'71 High Holborn. London WClR 4TP_ Further copiesmaybe obtainedfrom ThePatentOffice Sales Branch, St Mary Cray. Orpington. Kent BR5 3RD. Printed by Multiplex techniques ltd, St Mary Cray. Kent, Con. V87
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3744542A DE3744542B4 (en) | 1987-12-30 | 1987-12-30 | Pharmaceutical use of L-δ-hydroxylysine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8900048D0 GB8900048D0 (en) | 1989-03-01 |
| GB2226759A true GB2226759A (en) | 1990-07-11 |
Family
ID=6343857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8900048A Withdrawn GB2226759A (en) | 1987-12-30 | 1989-01-04 | Pharmaceutical compositions containing lysine |
Country Status (3)
| Country | Link |
|---|---|
| CH (1) | CH678490A5 (en) |
| DE (1) | DE3744542B4 (en) |
| GB (1) | GB2226759A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3912477A1 (en) * | 1989-04-15 | 1990-10-18 | Mueller Robert Dr | OUTSTANDING PRAEPARATE AND ITS USE |
| IT1407715B1 (en) * | 2010-06-18 | 2014-04-30 | Alphrema Srl | COMPOSITIONS FOR TOPICAL USE FOR PROPHYLAXIS AND HYGIENIC TREATMENT OF SOME PROBLEMS OF ANO-RECTAL PATHOLOGY, LIKE HEMORROIDES, RAGADI, ASCESSES AND FISTULAS. |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1210968A (en) * | 1967-10-11 | 1970-11-04 | Far Eastern Detailers Ltd | Improvements in or relating to the treatment of gastric ailments |
| GB1219869A (en) * | 1968-07-24 | 1971-01-20 | Farmaceutici Italia | Stabilized estrogen sulphate salts |
| GB1381649A (en) * | 1971-10-13 | 1975-01-22 | Tixier G | Medicine comprising lysine by-products |
| GB1399887A (en) * | 1971-06-10 | 1975-07-02 | Prockop D J | Composition and methods for controlling collagen synthesis |
| EP0163111A2 (en) * | 1984-04-28 | 1985-12-04 | Kyowa Hakko Kogyo Co., Ltd. | Method for solubilization of interferon |
| GB2181647A (en) * | 1985-10-01 | 1987-04-29 | Jean Morelle | Compositions based on lysine and arginine salts |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3728852C2 (en) * | 1987-08-28 | 2003-06-18 | Wilhelm Hoerrmann | Medicines for tumor therapy |
-
1987
- 1987-12-30 DE DE3744542A patent/DE3744542B4/en not_active Expired - Fee Related
-
1988
- 1988-12-21 CH CH4684/88A patent/CH678490A5/de not_active IP Right Cessation
-
1989
- 1989-01-04 GB GB8900048A patent/GB2226759A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1210968A (en) * | 1967-10-11 | 1970-11-04 | Far Eastern Detailers Ltd | Improvements in or relating to the treatment of gastric ailments |
| GB1219869A (en) * | 1968-07-24 | 1971-01-20 | Farmaceutici Italia | Stabilized estrogen sulphate salts |
| GB1399887A (en) * | 1971-06-10 | 1975-07-02 | Prockop D J | Composition and methods for controlling collagen synthesis |
| GB1381649A (en) * | 1971-10-13 | 1975-01-22 | Tixier G | Medicine comprising lysine by-products |
| EP0163111A2 (en) * | 1984-04-28 | 1985-12-04 | Kyowa Hakko Kogyo Co., Ltd. | Method for solubilization of interferon |
| GB2181647A (en) * | 1985-10-01 | 1987-04-29 | Jean Morelle | Compositions based on lysine and arginine salts |
Non-Patent Citations (3)
| Title |
|---|
| JP-57/67513 A2 * |
| JP-58/177995 A2 * |
| The Extra Pharmacopoeia (MARTINDALE),28th Ed. p.56 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8900048D0 (en) | 1989-03-01 |
| DE3744542A1 (en) | 1989-07-13 |
| CH678490A5 (en) | 1991-09-30 |
| DE3744542B4 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4626536A (en) | Compositions for combatting toxaemia | |
| US4496545A (en) | Nonapeptide for treating addictive drug withdrawal conditions | |
| DE69713485T2 (en) | Medicines for the treatment or prevention of thrombocytopenia | |
| EP0139534B1 (en) | Compositions for the prophylactic treatment of osteitis and osteomyelitis | |
| GR3031448T3 (en) | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine. | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| JPS5998015A (en) | Immunoactivator | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| AU693076B2 (en) | Arsenic medicaments for the treatment of chronic fatigue syndrome | |
| US4861587A (en) | Use of TNF for the prevention or treatment of radiation damage | |
| US4882336A (en) | Method and pharmaceutical composition for treating leukoencephalitic demyelinization clinical patterns of autoimmune origin, particularly multiple sclerosis | |
| GB2226759A (en) | Pharmaceutical compositions containing lysine | |
| US3852453A (en) | Method of enhancing vincamine compositions | |
| KR890004705A (en) | Antiviral agents | |
| US5665371A (en) | Medicines which contain derivatives of proline or hydroxyproline | |
| Kirby | Vancomycin therapy of staphylococcal infections | |
| US4686225A (en) | Vinpocetine for pulmonary hemorrhage and edema | |
| US3873709A (en) | Method of treating psychosis | |
| US5955498A (en) | Agent for prophylaxis and therapy of diseases | |
| CA1170184A (en) | Psychotropic drugs | |
| US4062974A (en) | Method for treating drepanocytosis | |
| Massimo et al. | Control of pain with sublingual buprenorphine in children with cancer | |
| Stratigos et al. | Treatment of gonorrhoea with spectinomycin hydrochloride | |
| GB2064958A (en) | Medicaments containing aspirin | |
| US4443472A (en) | Method of treating mammals for effects of neuro- and cardiovascular toxins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |